Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Operating Leases (2019 - 2025)

Historic Operating Leases for Macrogenics (MGNX) over the last 7 years, with Q3 2025 value amounting to $31.9 million.

  • Macrogenics' Operating Leases rose 855.7% to $31.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 855.7%. This contributed to the annual value of $32.6 million for FY2024, which is 795.14% up from last year.
  • As of Q3 2025, Macrogenics' Operating Leases stood at $31.9 million, which was up 855.7% from $32.1 million recorded in Q2 2025.
  • Macrogenics' Operating Leases' 5-year high stood at $32.6 million during Q4 2024, with a 5-year trough of $17.0 million in Q3 2022.
  • Over the past 5 years, Macrogenics' median Operating Leases value was $29.9 million (recorded in 2024), while the average stood at $27.0 million.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 2281.04% in 2022, then surged by 7753.66% in 2023.
  • Over the past 5 years, Macrogenics' Operating Leases (Quarter) stood at $20.8 million in 2021, then soared by 44.8% to $30.1 million in 2022, then rose by 0.3% to $30.2 million in 2023, then rose by 7.95% to $32.6 million in 2024, then dropped by 2.24% to $31.9 million in 2025.
  • Its Operating Leases stands at $31.9 million for Q3 2025, versus $32.1 million for Q2 2025 and $32.1 million for Q1 2025.